NASDAQ:GRCE

Grace Therapeutics Q1 2027 Earnings Results & Report

Grace Therapeutics logo
$1.71 -0.02 (-1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$1.70 -0.01 (-0.35%)
As of 05:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Grace Therapeutics missed analyst earnings expectations in its Q1 2027 results, released August 14, 2026. The company reported EPS of -$0.91 versus the -$0.1293 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2027
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 AM ET

Grace Therapeutics EPS Results

Actual EPS
-$0.91
Consensus EPS
-$0.1293
Beat/Miss
Missed by -$0.7807
One Year Ago EPS
-$0.21
EPS Beat Rate
5 of last 8 quarters

Grace Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$400 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Grace Therapeutics Q1 2027 Earnings FAQ

Grace Therapeutics (NASDAQ:GRCE) reported earnings of -$0.91 per share for Q1 2027, missing the consensus estimate of -$0.1293. The report was announced on Friday, August 14, 2026.

Grace Therapeutics Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Grace: Fiscal Q2 earnings snapshot
See More Grace Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Grace Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Grace Therapeutics and other key companies, straight to your email.

About Grace Therapeutics

Grace Therapeutics (NASDAQ:GRCE) is a clinical-stage biopharmaceutical company developing medicines for rare and orphan diseases. Its drug candidates are designed to address conditions with limited treatment options, including neurological disorders.

The company’s pipeline includes GTX-104, a formulation of nimodipine being developed for patients with aneurysmal subarachnoid hemorrhage, as well as GTX-102 for ataxia-telangiectasia and GTX-101 for postherpetic neuralgia. These programs use alternative delivery approaches intended to address limitations associated with existing treatments.

Grace Therapeutics was formerly known as Acasti Pharma and adopted its current name as it focused on the development programs associated with Grace Therapeutics. The company’s candidates remain investigational and are not approved medicines.

View Grace Therapeutics Profile